<div id="readability-page-1"><p>CVS Health (NYSE:CVS - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 6.600-6.700 for the period, compared to the consensus estimate of 6.610. The company issued revenue guidance of $400.0 billion-$400.0 billion, compared to the consensus revenue estimate of $399.0 billion.</p><h2>Analysts Set New Price Targets</h2><ul><li>CVS Health Gains as Revenue Grows, Dividend Remains Strong</li></ul><p>CVS has been the subject of several recent research reports. Morgan Stanley increased their target price on shares of CVS Health from $89.00 to $93.00 and gave the stock an &#34;overweight&#34; rating in a research note on Wednesday, December 10th. Wells Fargo &amp; Company decreased their price objective on CVS Health from $103.00 to $102.00 and set an &#34;overweight&#34; rating for the company in a research report on Thursday, November 13th. TD Cowen lifted their target price on CVS Health from $100.00 to $105.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, December 10th. Raymond James Financial upped their price target on CVS Health from $75.00 to $90.00 in a research note on Friday, October 31st. Finally, Wolfe Research lifted their price objective on shares of CVS Health from $85.00 to $100.00 and gave the company an &#34;outperform&#34; rating in a research report on Monday, December 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have issued  a Buy rating and four have assigned  a Hold rating to the company. Based on data from MarketBeat, CVS Health  has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $94.67.</p><p><b>Get Our Latest Report on CVS Health</b></p><h2>CVS Health Trading Down 0.4%</h2><ul><li>MarketBeat Week in Review – 05/12 - 05/16</li></ul><p>Shares of CVS stock opened at $77.95 on Thursday. CVS Health has a 1-year low of $43.56 and a 1-year high of $85.15. The company has a debt-to-equity ratio of 0.83, a current ratio of 0.83 and a quick ratio of 0.63. The business's fifty day moving average price is $79.08 and its 200 day moving average price is $72.24. The firm has a market capitalization of $98.95 billion, a PE ratio of 205.14, a P/E/G ratio of 0.77 and a beta of 0.48. </p><p>CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.36 by $0.24. The business had revenue of $102.87 billion during the quarter, compared to the consensus estimate of $98.85 billion. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. The business's revenue was up 7.8% compared to the same quarter last year. During the same quarter last year, the firm posted $1.09 EPS. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS.  As a group, sell-side analysts forecast that  CVS Health will post 5.89 EPS for the current fiscal year. </p><h2>Hedge Funds Weigh In On CVS Health</h2><ul><li>Is It Time to Buy the Dip in Novo Nordisk Stock?</li></ul><p>Several hedge funds and other institutional investors have recently bought and sold shares of the company. State Street Corp grew its holdings in  CVS Health by 0.3% in the third quarter. State Street Corp now owns 58,938,286 shares of the pharmacy operator's stock valued at $4,443,357,000 after purchasing an additional 149,701 shares during the last quarter.  Ameriprise Financial Inc. raised its stake in shares of  CVS Health by 5.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 7,855,845 shares of the pharmacy operator's stock worth $541,903,000 after buying an additional 385,806 shares during the last quarter.  Amundi boosted its position in shares of  CVS Health by 95.3% in the 3rd quarter. Amundi now owns 7,453,980 shares of the pharmacy operator's stock worth $572,665,000 after buying an additional 3,637,943 shares in the last quarter.  Wellington Management Group LLP grew its stake in  CVS Health by 391.6% in the 3rd quarter. Wellington Management Group LLP now owns 6,330,717 shares of the pharmacy operator's stock valued at $477,273,000 after acquiring an additional 5,042,816 shares during the last quarter.  Finally, Raymond James Financial Inc. increased its holdings in  CVS Health by 4.4% during the 2nd quarter. Raymond James Financial Inc. now owns 3,191,584 shares of the pharmacy operator's stock valued at $220,155,000 after acquiring an additional 133,875 shares in the last quarter. 80.66% of the stock is owned by institutional investors and hedge funds. </p><h2>CVS Health Company Profile</h2> (Get Free Report)<p>CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy &amp; Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than CVS Health</li><li>What is MarketRank™? How to Use it</li><li>Rate Cuts Make These 3 Income ETFs More Attractive Than Ever</li><li>Insider Selling Explained: Can it Inform Your Investing Choices?</li><li>Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport</li><li>Best Energy Stocks - Energy Stocks to Buy Now</li><li>Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in CVS Health Right Now?</h2><p>Before you consider CVS Health, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.</p><p>While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>CVS Health updated its FY 2025 earnings guidance, projecting EPS of 6.600-6.700, above the consensus estimate of 6.610, and revenue guidance of $400 billion, surpassing the consensus of $399 billion. Analysts have adjusted their price targets, with a consensus rating of 'Moderate Buy' and a target of $94.67. CVS Health's recent quarterly earnings exceeded expectations, with a net margin of 0.12% and a return on equity of 11.45%. Institutional investors have increased their holdings in the company.</p>

CVS Health (NYSE:CVS) Issues FY 2025 Earnings Guidance